152 related articles for article (PubMed ID: 10828686)
1. Keyhole limpet hemocyanin immunotherapy of bladder cancer: laboratory and clinical studies.
Lamm DL; Dehaven JI; Riggs DR
Eur Urol; 2000; 37 Suppl 3():41-4. PubMed ID: 10828686
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of murine bladder cancer with keyhole limpet hemocyanin (KLH).
Lamm DL; DeHaven JI; Riggs DR; Ebert RF
J Urol; 1993 Mar; 149(3):648-52. PubMed ID: 8437283
[TBL] [Abstract][Full Text] [Related]
3. Keyhole limpet hemocyanin immunotherapy of murine bladder cancer.
Lamm DL; DeHaven JI; Riggs DR; Delgra C; Burrell R
Urol Res; 1993 Jan; 21(1):33-7. PubMed ID: 8456536
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy with keyhole limpet hemocyanin: efficacy and safety in the MB-49 intravesical murine bladder tumor model.
Swerdlow RD; Ratliff TL; La Regina M; Ritchey JK; Ebert RF
J Urol; 1994 Jun; 151(6):1718-22. PubMed ID: 8189604
[TBL] [Abstract][Full Text] [Related]
5. Keyhole-limpet hemocyanin immunotherapy in the bilharzial bladder: a new treatment modality? Phase II trial: superficial bladder cancer.
Wishahi MM; Ismail IM; Ruebben H; Otto T
J Urol; 1995 Mar; 153(3 Pt 2):926-8. PubMed ID: 7853576
[TBL] [Abstract][Full Text] [Related]
6. Keyhole limpet haemocyanin in experimental bladder cancer: literature review and own results.
Linn JF; Black P; Derksen K; Rübben H; Thüroff JW
Eur Urol; 2000; 37 Suppl 3():34-40. PubMed ID: 10828685
[TBL] [Abstract][Full Text] [Related]
7. Keyhole limpet hemocyanin for carcinoma in situ of the bladder: a long-term follow-up study.
Jurincic-Winkler CD; Metz KA; Beuth J; Klippel KF
Eur Urol; 2000; 37 Suppl 3():45-9. PubMed ID: 10828687
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of local Bacillus Calmette-Guérin treatment in superficial bladder cancer relapsing under Keyhole-Limpet Hemocyanin immunotherapy.
Jurincic-Winkler C; Engelmann U; Beuth J; Klippel KF
Zentralbl Bakteriol; 1995 Oct; 282(4):409-15. PubMed ID: 9810664
[TBL] [Abstract][Full Text] [Related]
9. Antibody response to keyhole limpet hemocyanin (KLH) treatment in patients with superficial bladder carcinoma.
Jurincic-Winkler CD; von der Kammer H; Beuth J; Scheit KH; Klippel KF
Anticancer Res; 1996; 16(4A):2105-10. PubMed ID: 8712751
[TBL] [Abstract][Full Text] [Related]
10. Superficial bladder cancer therapy.
Schenkman E; Lamm DL
ScientificWorldJournal; 2004 Jun; 4 Suppl 1():387-99. PubMed ID: 15349563
[TBL] [Abstract][Full Text] [Related]
11. Recurrent superficial transitional cell carcinoma of the bladder: adjuvant topical chemotherapy versus immunotherapy. A prospective randomized trial.
Flamm J; Bucher A; Höltl W; Albrecht W
J Urol; 1990 Aug; 144(2 Pt 1):260-3. PubMed ID: 2197428
[TBL] [Abstract][Full Text] [Related]
12. Superiority of intravesical immunotherapy with Corynebacterium parvum and Allium sativum in control of murine bladder cancer.
Marsh CL; Torrey RR; Woolley JL; Barker GR; Lau BH
J Urol; 1987 Feb; 137(2):359-62. PubMed ID: 3806842
[TBL] [Abstract][Full Text] [Related]
13. Urinary interleukin-1 alpha levels are increased by intravesical instillation with keyhole limpet hemocyanin in patients with superficial transitional cell carcinoma of the bladder.
Jurincic-Winkler CD; Gallati H; Alvarez-Mon M; Sippel J; Carballido J; Klippel KF
Eur Urol; 1995; 28(4):334-9. PubMed ID: 8575503
[TBL] [Abstract][Full Text] [Related]
14. Effect of keyhole limpet hemocyanin (KLH) and bacillus Calmette-Guérin (BCG) instillation on carcinoma in situ of the urinary bladder.
Jurincic-Winkler C; Metz KA; Beuth J; Sippel J; Klippel KF
Anticancer Res; 1995; 15(6B):2771-6. PubMed ID: 8669862
[TBL] [Abstract][Full Text] [Related]
15. Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trial.
Lammers RJ; Witjes WP; Janzing-Pastors MH; Caris CT; Witjes JA
J Clin Oncol; 2012 Jun; 30(18):2273-9. PubMed ID: 22585689
[TBL] [Abstract][Full Text] [Related]
16. [Topical immunotherapy (KLH) vs. chemotherapy (Ethoglucid) in prevention of recurrence of superficial bladder cancer. A prospective randomized study].
Flamm J; Donner G; Bucher A; Höltl W; Albrecht W; Havelec L
Urologe A; 1994 Mar; 33(2):138-43. PubMed ID: 8178408
[TBL] [Abstract][Full Text] [Related]
17. Keyhole limpet hemocyanine can enhance the natural killer activity of patients with transitional cell carcinoma of the bladder.
Moltó LM; Carballido J; Jurincic C; Lapeña P; Manzano L; Salmerón I; Klippel KF; Alvarez-Mon M
Eur Urol; 1991; 19(1):74-8. PubMed ID: 2007423
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized study.
Jurincic CD; Engelmann U; Gasch J; Klippel KF
J Urol; 1988 Apr; 139(4):723-6. PubMed ID: 3127600
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapeutic Potential of Mollusk Hemocyanins in Combination with Human Vaccine Adjuvants in Murine Models of Oral Cancer.
Mora Román JJ; Del Campo M; Villar J; Paolini F; Curzio G; Venuti A; Jara L; Ferreira J; Murgas P; Lladser A; Manubens A; Becker MI
J Immunol Res; 2019; 2019():7076942. PubMed ID: 30847353
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant topical chemotherapy versus immunotherapy in primary superficial transitional cell carcinoma of the bladder.
Flamm J; Bucher A
Br J Urol; 1991 Jan; 67(1):70-3. PubMed ID: 1993279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]